<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794022</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL22_0991</org_study_id>
    <nct_id>NCT05794022</nct_id>
  </id_info>
  <brief_title>Cohort of STEMI Patients 2</brief_title>
  <acronym>HIBISCUS STEMI</acronym>
  <official_title>CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ST-segment elevation myocardial infarction (STEMI) is an acute condition that accounts for&#xD;
      75% of sudden deaths in adults over 35 years of age and more than half of all cases of&#xD;
      chronic heart failure. However, the mechanism of myocardial infarction remains poorly&#xD;
      understood. At present, there is no national information system for myocardial infarction, as&#xD;
      there is for other diseases such as multiple sclerosis (OFSEP cohort).&#xD;
&#xD;
      The purpose of this cohort is to enable studies and research projects to be carried out on&#xD;
      the descriptive epidemiology of myocardial infarction, monitoring of patients undergoing&#xD;
      treatment (safety, efficacy), quality of life and functional consequences of infarction, and&#xD;
      research into new biological and imaging prognostic biomarkers. Its general objective is to&#xD;
      provide researchers, hospital practitioners, medical interns, academics or industrialists&#xD;
      with a quality epidemiological tool for research.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Research of potential new markers</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarkers assays (prognosis and diagnosis) between inclusion and one-year follow-up (H0, H4, H24, H48, M1, M12 since emergency revascularisation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculation of infarct size on MRI</measure>
    <time_frame>1 month</time_frame>
    <description>Measurement of reperfusion lesions on MRI (mass in grams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoepidemiology of myocardial infarction.</measure>
    <time_frame>5 years</time_frame>
    <description>Description and evolution of patients' medical treatment between hospital discharge and 5 years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events between inclusion and 5 years follow-up</measure>
    <time_frame>5 years</time_frame>
    <description>Time to a major adverse cardiovascular event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cohort group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient with ST-segment elevation myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>1 MRI at 1 month with gadolinium injection</description>
    <arm_group_label>Cohort group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biocollection</intervention_name>
    <description>Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.</description>
    <arm_group_label>Cohort group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of life questionaries</intervention_name>
    <description>EQ-5D-5L and HAD questionaries at 1 month and 1 year.</description>
    <arm_group_label>Cohort group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a&#xD;
             12-lead ECG.&#xD;
&#xD;
          -  Management in primary ACT&#xD;
&#xD;
          -  Prior oral informed consent followed by signed informed consent as soon as possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of STEMI not confirmed on angiography&#xD;
&#xD;
          -  Inability to give the subject informed information&#xD;
&#xD;
          -  Lack of coverage by a social security scheme&#xD;
&#xD;
          -  Obvious contraindication to injected magnetic resonance imaging (claustrophobia,&#xD;
             pacemaker, defibrillator, or a metallic body (ferromagnetic), severe renal&#xD;
             insufficiency (GFR&lt;30 ml/min), known allergy to the contrast medium ....)&#xD;
&#xD;
          -  Pregnant woman or woman of childbearing age without effective contraception,&#xD;
             breastfeeding woman.&#xD;
&#xD;
          -  Deprivation of civil rights (curators, guardianship, safeguard of justice)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas BOCHATON, Dr</last_name>
    <phone>04 72 35 75 41</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.bochaton@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne VARILLON</last_name>
    <phone>04 72 35 69 64</phone>
    <phone_ext>+33</phone_ext>
    <email>yvonne.varillon@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <state>Rhone</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas BOCHATON, Dr</last_name>
      <phone>04 72 35 75 41</phone>
      <phone_ext>+33</phone_ext>
      <email>thomas.bochaton@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Rhone</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Brahim HARBAOUI, Pr</last_name>
      <phone>04 72 35 58 25</phone>
      <phone_ext>+33</phone_ext>
      <email>brahim.harbaoui@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 6, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>bio-collection</keyword>
  <keyword>Imaging markers</keyword>
  <keyword>biomarkers</keyword>
  <keyword>STEMI</keyword>
  <keyword>clinical outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

